Baker Bros. Advisors KALA Position
Active3-Fund ConvergenceBaker Bros. Advisors increased their position in KALA BIO, Inc. (KALA) in Q4 2025, holding $1.0M worth of shares across 1,804,055 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
KALA is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About KALA BIO, Inc.
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Full company profile →Short Interest
0.8%
0.4 days to cover
Baker Bros. Advisors KALA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 1,804,055 | +818,962 | $1.0M |
| Q3 2025 | Decreased | 985,093 | -216,801 | $1.5M |
| Q2 2025 | Held | 1,201,894 | — | $5.7M |
| Q1 2025 | Held | 1,201,894 | — | $6.9M |
| Q4 2024 | Increased | 1,201,894 | +310,559 | $8.3M |
| Q3 2024 | Held | 891,335 | — | $5.1M |
| Q2 2024 | Increased | 891,335 | +624,722 | $6.3M |
| Q1 2024 | Held | 266,613 | — | $2.1M |
| Q4 2023 | Held | 266,613 | — | $1.9M |
| Q3 2023 | Increased | 266,613 | +150,400 | $2.4M |
| Q2 2023 | Increased | 116,213 | +39,400 | $1.7M |
| Q1 2023 | New | 76,813 | +76,813 | $1.2M |
Frequently Asked Questions
Does Baker Bros. Advisors own KALA?
Yes. As of Q4 2025, Baker Bros. Advisors holds 1,804,055 shares of KALA BIO, Inc. (KALA) valued at $1.0M. This data comes from their SEC 13F filing.
How many hedge funds own KALA?
3 specialist biotech hedge funds currently hold KALA, including Cormorant Asset Management, Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy KALA?
Baker Bros. Advisors's position in KALA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's KALA position increasing or decreasing?
Baker Bros. Advisors increased their KALA position in the most recent quarter, adding 818,962 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KALACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →